Seaport Therapeutics Inc(SPTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.59 | Insider Own | 74.22% | Shs Outstand | 53.5M | Perf Week | 8.76% |
| Market Cap | 1.18B | Forward P/E | - | EPS next Y | 40.61% | Insider Trans | 0.05% | Shs Float | 13.8M | Perf Month | 28.1% |
| Enterprise Value | 0.89B | PEG | - | EPS next Q | -0.56 | Inst Own | 34.38% | Short Float | 27.05% | Perf Quarter | -7.69% |
| Income | -0.14B | P/S | - | EPS this Y | 86.89% | Inst Trans | 51.56% | Short Ratio | 16.32 | Perf Half Y | 37.74% |
| Sales | 0.00B | P/B | 2.96 | EPS next 5Y | 57.09% | ROA | - | Short Interest | 3.73M | Perf YTD | 4.62% |
| Book/sh | 7.42 | P/C | 4.05 | EPS past 3/5Y | - | ROE | - | 52W High | -22.6% ($28.38) | Perf Year | - |
| Cash/sh | 5.43 | P/FCF | - | Sales past 3/5Y | - | ROIC | -34.59% | 52W Low | 47.95% ($14.85) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 6.73% 7.51% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.48 | EPS Q/Q | -17.1% | Profit Margin | - | RSI (14) | 59.68 | Recom | 1.22 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.48 | Sales Q/Q | - | SMA20 | 9.73% ($20.02) | Beta | - | Target Price | $37.12 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/11/2 | SMA50 | 6.66% ($20.6) | Rel Volume | 1.32 | Prev Close | $21.92 |
| Employees | 54 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 13.81% - | SMA200 | 8.89% ($20.18) | Avg Volume(3M) | 0.23M | Price | $21.97 |
| IPO | 2026/5/1 | Option/Short | No/Yes | Trades | 2922 | Volume | 301,054 | Change | 0.21% |
🧠 Support Therapeutics (SPTX) is a U.S. clinical-stage biotech company developing treatments for neuropsychiatric disorders such as depression and anxiety. The company pursues a differentiated approach based on Glyph, its lymphatic-targeting prodrug technology, which is designed to enhance oral bioavailability and reduce side effects. Its pipeline includes lead candidates such as an oral neurosteroid program targeting anxious depression.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded more than usual. That is 132% of its average volume.
SPTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +86.9% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
27.1% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #148 of 597 in the industry
Based on market cap of $1B.
SLN#146 Silence Therapeutics Plc ADR $1B PER - 
VOR#147 Vor Biopharma Inc $1B PER 0.5 SPTX#148 Seaport Therapeutics Inc $1B PER - 
SGP#149 SpyGlass Pharma Inc $1B PER - 
ANRO#150 Alto Neuroscience Inc $1B PER - 
FAQ
What kind of company is SPTX?
SPTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SPTX?
The market cap of SPTX is approximately $1.2B, ranking 2,452 within its sector.
What is the 52-week high and low for SPTX?
SPTX has recorded a 52-week high of $28.38 and a low of $14.85.
